• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>New biotechnology >Mapping ethical and social aspects of cancer biomarkers
【24h】

Mapping ethical and social aspects of cancer biomarkers

机译：绘制癌症生物标志物的伦理和社会方面的图谱

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Cancer biomarkers represent a revolutionary advance toward personalised cancer treatment, promising therapies that are tailored to subgroups of patients sharing similar generic traits. Notwithstanding the optimism driving this development, biomarkers also present an array of social and ethical questions, as witnessed in sporadic debates across different literatures. This review article seeks to consolidate these debates in a mapping of the complex terrain of ethical and social aspects of cancer biomarker research. This mapping was undertaken from the vantage point offered by a working cancer biomarker research centre called the Centre for Cancer Biomarkers (CCBIO) in Norway, according to a dialectic move between the literature and discussions with researchers and practitioners in the laboratory. Starting in the lab, we found that, with the exception of some classical bioethical dilemmas, researchers regarded many issues relative to the ethos of the biomarker community; how the complexity and uncertainty characterising biomarker research influence their scientific norms of quality. Such challenges to the ethos of cancer research remain largely implicit, outside the scope of formal bioethical enquiry, yet form the basis for other social and ethical issues. Indeed, looking out from the lab we see how questions of complexity, uncertainty and quality contribute to debates around social and global justice; undermining policies for the prioritisation of care, framing the stratification of those patients worthy of treatment, and limiting global access to this highly sophisticated research. We go on to discuss biomarker research within the culturally-constructed 'war on cancer' and highlight an important tension between the expectations of 'magic bullets' and the complexity and uncertainty faced in the lab. We conclude by arguing, with researchers in the CCBIO, for greater reflexivity and humility in cancer biomarker research and policy. (C) 2016 The Author. Published by Elsevier B.V.
机译：癌症生物标志物代表着个性化癌症治疗的革命性进展，这是有前途的疗法，可针对具有相似通用特征的患者亚组量身定制。尽管乐观情绪推动了这一发展，但生物标志物也提出了一系列社会和伦理问题，这在不同文献的零星辩论中得到了证明。这篇综述文章旨在通过对癌症生物标志物研究的伦理和社会方面的复杂地形图进行整合，以巩固这些辩论。根据文献与实验室研究人员和实践者之间的辩证关系，这种映射是从挪威一个运作中的癌症生物标志物研究中心提供的优势进行的，该研究中心称为挪威癌症生物标志物中心（CCBIO）。从实验室开始，我们发现，除了一些经典的生物伦理困境之外，研究人员认为许多问题都与生物标志物群落的精神有关。生物标志物研究的复杂性和不确定性如何影响其科学的质量标准。在正式的生物伦理学研究范围之外，对癌症研究精神的此类挑战在很大程度上仍是隐性的，但却构成了其他社会和伦理问题的基础。确实，从实验室中观察，我们发现复杂性，不确定性和质量问题如何促进围绕社会和全球正义的辩论;破坏了优先治疗的政策，使那些值得治疗的患者分层，并限制了对这项高度复杂研究的全球访问。我们将继续在具有文化底蕴的“抗癌战争”中讨论生物标志物的研究，并强调“神奇子弹”的期望与实验室面临的复杂性和不确定性之间的重要矛盾。最后，我们与CCBIO的研究人员争辩说，在癌症生物标志物研究和政策方面具有更高的反射性和谦逊性。 （C）2016作者。由Elsevier B.V.发布

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号